Already established as cornerstone therapies in diabetes and obesity, GLP-1 receptor agonists have now cracked into the ...

Novo Nordisk stock crashed Friday after the firm's next-generation weight-loss drug missed expectations in a highly anticipated study.

Since Ozempic blasted onto the stage in 2017 with its approval for type 2 diabetes, drugmakers Novo Nordisk and Eli Lilly have been battling to leapfrog each other with newer and more effective ...

Viking Therapeutics has seen a significant drop, despite positive news and promising GLP-1 drug developments. Find out why ...

Specific types of essence are required to make some outfits in Infinity Nikki, but essence isn't something that's naturally unlocked as you play through the game. Instead, you need to turn to the ...

Sha'Carri Richardson appeared on the latest cover of Essence Magazine, her first cover appearance following a triumphant campaign at the Paris Olympics. The American sprinter anchored her nation ...

Israel's Netanyahu takes to the witness stand for the first time in his trial for alleged corruption TEL AVIV, Israel -- Israel's Netanyahu takes to the witness stand for the first time in his ...

Tirzepatide treatment led to a 47% greater relative reduction in weight compared with semaglutide. Topline results were announced from a phase 3b clinical trial comparing tirzepatide with ...

Part 1 of the ESSENCE trial evaluated the effect of once-weekly semaglutide 2.4 mg on liver tissue (histology) compared to placebo on top of standard of care for the first 800 randomised Bagsværd ...

Over 137 million U.S. adults qualify for semaglutide Semaglutide shows promise for treating multiple conditions, beyond obesity and diabetes The cost of semaglutide remains a significant barrier ...